anti-muc1 car-t cells

Anti-MUC1 CAR-T cells are a form of chimeric antigen receptor (CAR) T cell therapy engineered to target the mucin 1 (MUC1) antigen, which is overexpressed and aberrantly glycosylated in many solid tumors such as breast cancer, pancreatic cancer, non-small cell lung cancer, and esophageal cancer. These therapies involve collecting a patient's own (autologous) or donor-derived (allogeneic) T lymphocytes and genetically modifying them to express a synthetic receptor that recognizes MUC1 on tumor cells. Upon binding to MUC1-expressing tumor cells, the engineered T-cells become activated and mediate cytotoxicity against the malignant tissue. Preclinical studies have demonstrated significant efficacy in reducing tumor burden with minimal toxicity in animal models[1][2][4]. Clinical trials are ongoing for several cancers[3]. Some advanced versions include additional genetic modifications such as PD-1 knockout or cytokine armoring to enhance efficacy within immunosuppressive tumor microenvironments[3][8].

Other names

anti-MUC1 CAR T cell therapyanti-MUC-1 CAR T cell therapyanti-MUC 1 CAR T cell therapyanti-MUC1 CAR-transduced autologous T lymphocytesanti-MUC-1 CAR-transduced autologous T lymphocytesanti-MUC 1 CAR-transduced autologous T lymphocytesMUC1-targeted CAR-T cellsMUC-1-targeted CAR-T cellsMUC 1-targeted CAR-T cellsAnti-Tn-MUC1 CAR T cellsAnti-Tn-MUC-1 CAR T cellsAnti-Tn-MUC 1 CAR T cells